QuatRx garnered $44 million in a new round of venture capital. The money is earmarked for the completion of a Phase III and Phase II study of its two endocrine programs. There's also an early-stage trial of a lipid-lowering compound. Venrock led the round. QuatRx has now raised $116 million in venture capital since 2000. The Ann Arbor, MI-based company had filed for an IPO last year but pulled it citing unfavorable market conditions.
- here's the report on QuatRx from Private Equity Hub